openPR Logo
Press release

Glioma Diagnosis Market by Leading Manufacturers, Demand and Growth Overview 2019 to 2027

05-22-2020 04:19 PM CET | Health & Medicine

Press release from: Transparency Market Research

Glioma Diagnosis Market

Glioma Diagnosis Market

Glioma: A Common Type of Brain Tumor That can be Fatal

Glioma is a common type of tumor originating in the brain, which is formed in glial cells. Glial cells are cells in the brain, which surround and support neurons in the brain including astrocytes, oligodendrocytes, and ependymal cells.

Glioma can affect functioning of the brain and it can be fatal, depending on its location and severity of tumor

Glioma is of different types: astrocytomas, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas

Headache; seizures; numbness; weakness in the arms, the face, or the legs; and personality changes are some of the major symptoms observed in patients with glioma

Risk factors for the development of glioma range from old age (more common in adults between 45-65 years of age) and radiation exposure to family history of glioma

Various diagnostic methods are available for detection of glioma. Depending on severity of the disease, different types of treatments or therapies are suggested to patients.

Report Overview @

https://www.transparencymarketresearch.com/glioma-diagnosis-market.html

Key Drivers and Restraints of Global Glioma Diagnosis Market

Advancements in brain tumor diagnosis and growing prevalence of brain cancer are some of the major factors fueling the global glioma diagnosis market

For instance, as per the American Society of Clinical Oncology (ASCO), around 23,820 adults in the U.S. were diagnosed with primary cancerous tumors of the brain and the spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS (central nervous system) tumors in the country in the year.

Combination of most advanced diagnostic scanning techniques and rising awareness regarding various types of brain tumors are some of the major factors responsible for growth of the global glioma diagnosis market

Moreover, growing human exposure to radiations in recent times is leading to high rate of incidence of the brain cancer. This is another factor driving the global glioma diagnosis market.

Higher Costs of Diagnosis Hamper Global Market
Cost of diagnosis of the brain tumor is very high and it is unaffordable for patients in several developing countries. This high cost can adversely impact the global glioma diagnosis market.

Regrowth of tumor after treatment and surgery in several cases and adverse effects of chemotherapy are also projected to hamper the global market for glioma diagnosis during the forecast period

Get Brochure of the Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75851

Primary Tumor Type Segment Dominates Global Market

Based on tumor type, the global glioma diagnosis market can be bifurcated into primary tumors and secondary tumors
The primary tumors segment can be sub-divided into astrocytomas, ependymomas, brain stem gliomas, oligodendrogliomas, mixed gliomas, and others

The primary tumors segment dominates the global glioma diagnosis market, as primary tumors are more prevalent across the world
Low-grade Gliomas a Promising Grade Segment
In terms of grade, the global glioma diagnosis market can be segmented into low-grade gliomas, high-grade gliomas, and recurrent high-grade gliomas

Low-grade gliomas is expected to be the most lucrative segment in the next few years, due to availability of more treatment options and early detection of tumors of low grade

Request For Covid19 Impact Analysis -

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75851

PET Scan Segment Witnesses Strong Growth
In terms of diagnosis test, the global glioma diagnosis market can be classified into neurological exams, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, biopsy, electroencephalography (EEG), and others
The MRI segment accounted for a major market share in 2018. The PET scans segment is estimated to expand at a high CAGR during the forecast period, owing to better sensitivity and higher rate of precision offered by MRI for glioma diagnosis
Hospitals & Clinics a Dominant End-user Segment
Based on end-user, the global glioma diagnosis market can be segmented into hospitals & clinics, diagnostic imaging centers, cancer research institutes, and others

The hospitals & clinics segment dominated the global glioma diagnosis market in 2018, owing to the large number of admissions of cancer patients at hospitals and availability of advanced equipment at hospitals and clinics

North America to Lead Global Market for Glioma Diagnosis

In terms of region, the global glioma diagnosis market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America dominated the global glioma diagnosis market in 2018, due to high prevalence of brain tumor in the region, growing radiation exposure, and availability of advanced diagnostic devices in the region

Asia Pacific is likely to be a more promising market for glioma diagnosis in the next few years, due to large geriatric population, the large number of patients with cancer, and rise in awareness regarding diseases and their diagnosis in the region. As per a study published by NCBI in September 2011, the rate of prevalence of primary brain tumors in China was 24.56 per 100,000 people in 2006.

Pre Book Now @

https://www.transparencymarketresearch.com/checkout.php?rep_id=75851

Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: USA - Canada Toll Free: 866-552-3453
Website: http://www.transparencymarketresearch.com

About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glioma Diagnosis Market by Leading Manufacturers, Demand and Growth Overview 2019 to 2027 here

News-ID: 2055364 • Views: 104

More Releases from Transparency Market Research

Plexiform Neurofibroma Market Set to Grow According to Forecasts 2016 - 2024
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body. Read Report Overview - https://www.transparencymarketresearch.com/plexiform-neurofibroma-market.html The most commonly observed tumor is
Alzheimers Disease Therapeutics and Diagnostics Market to Reflect Impressive Gro …
Alzheimer's disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer's disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer's Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. Read Report Overview -
Decentralized Infectious Disease Testing Market to Make Great Impact in Near Fut …
With developing technological innovations in the health care sector comprising biosensors, smartphone apps, lab-on-chip and tech tops, that offer a nearer association with the patient. Decentralized testing techniques are therefore becoming a catalyst in the transformation of the health care sector. The main reason that this type of testing is trending nowadays is because of its access and quicker results. It can be done closer to the patient, the results
Cancer Hormone Therapy Market Research Report : Global Analysis 2015-2023
Hormones are natural substances made by our glands in our body and the network of glands that make hormones is termed as endocrine systems. These hormones are carried through bloodstream and act as a messenger between one part to another part of our body. Hormone therapy is one of the major modalities of medical treatment for cancers which involves manipulation of the endocrine systems through exogenous administration of steroid hormones

All 5 Releases


More Releases for Glioma

Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Malignant Glioma Market Trends & Projection to 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons
Optic Nerve Glioma Market Global Analysis & Forecast to 2023
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are
Optic Nerve Glioma Market Ultimate Analysis & Global Foreseen to 2023
Optic Nerve Glioma Market Analysis: By Key Companies- (Emcure Pharmaceuticals ltd., Sigma-Aldrich Co., Thermo Fisher Scientific Inc.,), by type (malignant optic nerve glioma, benign optic nerve glioma) by diagnosis (neurological exam, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), biopsy, others), by treatment (surgery, radiation therapy, chemotherapy, others) by end users (hospitals & clinics, diagnostic centers, others) - Global forecast till 2023 Optic nerve glioma or optic glioma or juvenile
Optic Nerve Glioma Market Absolute Analysis & Global Forecast to 2023
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are
Malignant Glioma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Malignant Glioma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Malignant Glioma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Malignant Glioma by development stage, therapy type, route of